News about Global Pharma

Biolyst Scientific Announced as New Brand Name to Encompass EMS and Azer

Biolyst Scientific has announced its new brand name, reflecting the integration of Electron Microscopy Sciences (EMS) and Azer Scientific.

Global Pharma | 23/07/2024 | By Aishwarya |  755

K2 Laboratory Bags NDC Codes for Two Investigational Drugs

K2 Laboratory has recently announced that its two investigational drugs, Brain Rehabilitation oral solution and Telomerase Inhibitor oral solution, have successfully obtained National Drug Code (NDC) numbers.

Global Pharma | 22/07/2024 | By Aishwarya |  619

ForDoz Secures US FDA Approval for Doxorubicin Hydrochloride Liposome Injection

Lupin has announced that its alliance partner, ForDoz Pharma Corp. has received approval from US FDA for its Abbreviated New Drug Application for Doxorubicin Hydrochloride Liposome Injection, Single-Dose Vials, to market a generic equivalent of Doxil Liposom.

Global Pharma | 22/07/2024 | By Aishwarya |  773

MOLLI Surgical to Adopt MOLLI Surgical's Breast Cancer Technology

MOLLI Surgical's wire-free and radiation-free technology for localizing lesions for breast cancer surgery improves the patient experience and has earned praise from surgeons for its accuracy and ease of use.

Global Pharma | 19/07/2024 | By Manvi |  473

Wearable Medical Devices Market Size Set to Grow by USD 26.55 Bn from 2024-2028

The market is estimated to grow at a CAGR of almost 23.31% during the forecast period. Increasing prevalence of chronic diseases globally is driving market growth, with a trend towards emergence of innovative wearable medical devices.

Global Pharma | 19/07/2024 | By Manvi |  578

Nipro Establishes New Medical Device Manufacturing Facility in North Carolina

Nipro Medical Corporation has announced expansion in the United States with the establishment of its first North American manufacturing facility in Greenville, North Carolina.

Global Pharma | 18/07/2024 | By Aishwarya |  1112

Mabwell Gets NMPA Approval for Clinical Trial of Nectin-4 Targeting ADC in TNBC

Mabwell has announced that its novel Nectin-4 targeting ADC has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD-1 inhibitor for the treatment of triple-negative breast cancer (TNBC).

Global Pharma | 16/07/2024 | By Aishwarya |  281

Modicus Prime Secures USD 3.5 Million in Series Seed Funding

Modicus Prime has received USD 3.5 million in series seed funding led by Silverton Partners, with additional backing from Alumni Ventures and other leading venture firms.

Global Pharma | 16/07/2024 | By Aishwarya |  604

AusperBio Receives USD 37 Million in Series A Financing Round

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. has announced the completion of a USD 37 million Series A financing round.

Global Pharma | 16/07/2024 | By Aishwarya |  629

Alembic Pharma Gets USFDA Tentative Approval for Selexipag for Injection

Alembic Pharmaceuticals has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial.

Global Pharma | 15/07/2024 | By Aishwarya |  906